Biocon Limited, a global biopharmaceutical company, announced the inauguration of its first U.S. manufacturing facility in Cranbury. The state-of-the-art plant, operated by its subsidiary Biocon Generics Inc (BGI), was formally launched by New Jersey Gov. Phil Murphy on Sept. 10.
Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested more than $30 million to upgrade it. The plant has an annual production capacity of 2 billion tablets. This strategic investment will help the company diversify its manufacturing base and strengthen its supply chain to meet the growing demand for its products in the U.S.
Kiran Mazumdar-Shaw, chairperson of Biocon Group, said the facility marks a “new chapter in our journey of global expansion” and reaffirms the company’s commitment to serving patients worldwide. The presence of Governor Murphy at the event underscores the importance of the project in fostering innovation and creating job opportunities in New Jersey, a state known as the “medicine chest to the world.”
The Cranbury facility is expected to enable faster access to essential therapies and improve supply reliability for patients across the United States. Siddharth Mittal, CEO and managing director of Biocon Ltd, stated, “This strategic investment brings us closer to patients, healthcare providers, and partners in this important market.”
